Whitehawk Therapeutics, Inc. (WHWK): M&A transaction — Whitehawk completes sale of Aadi Subsidiary to Kaken for $102.4M cash

Whitehawk Therapeutics, Inc.

Sale of 100% of Aadi Subsidiary, Inc. to KAKEN INVESTMENTS INC. closed on March 25, 2025.
Cash purchase price of $102.4 million after adjustments paid by Purchaser.
Pro forma financial information to be filed by amendment within four business days.
Deal previously announced on December 19, 2024 under Stock Purchase Agreement.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Whitehawk Therapeutics, Inc. completed a disposition involving KAKEN INVESTMENTS INC. for $102.4 million (closed 2025-03-25).

Action: disposition
Counterparty: KAKEN INVESTMENTS INC.
Consideration: $102.4 million
Closing: 2025-03-25

Exact text from the filing

and Aadi Subsidiary, Inc. on December 19, 2024. In accordance with the Purchase Agreement, upon the closing of the Divestiture, Purchaser paid to the Company a cash payment of $102.4 million (following applicable purchase price adjustments under the Purchase Agreement). The foregoing description of the Divestiture and the Purchase Agreement does not purport to be

View on SEC.gov

20 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-063253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.